Concert Pharmaceuticals is a leading company for the development of treatments similar to topical tofacitinib and topical ruxolitinib, both of which are topical JAK inhibitors.

Recent trials and treatment analysis have shown positive results for regrowth in patients with Alopecia Areata.

For more information, please follow the links below:

Concert Pharmaceuticals:

https://www.concertpharma.com/

Scientific Presentation:

https://www.concertpharma.com/wp-content/uploads/2018/11/CTP-543-Phase-2a-Topline-Results-FINAL-12NOV18.pdf

Nov 12th 2018 Press Release:

http://ir.concertpharma.com/index.php/news-releases/news-release-details/concert–pharmaceuticals-reports-positive-ctp-543-results-interim

Jan 22nd 2018 Press Release:

http://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-completes-enrollment-12-mg-cohort-phase

More Alopecia Areata Information:

https://alopeciaareataresearch.com/